These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6211231)
21. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske AR Cancer Chemother Pharmacol; 2000; 46(2):167-71. PubMed ID: 10972487 [TBL] [Abstract][Full Text] [Related]
22. [Phase II study of 4'-O-tetrahydropyranyladriamycin(THP-ADM)]. Nakada H; Ogawa M; Miyamoto H; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Usui N; Adachi K; Okada Y Gan To Kagaku Ryoho; 1984 Jan; 11(1):138-42. PubMed ID: 6696455 [TBL] [Abstract][Full Text] [Related]
23. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Ajani JA; Dimery I; Chawla SP; Pinnamaneni K; Benjamin RS; Legha SS; Krakoff IH Cancer Treat Rep; 1986 Mar; 70(3):375-9. PubMed ID: 3955548 [TBL] [Abstract][Full Text] [Related]
24. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma. Gralla RJ; Yagoda A Cancer Treat Rep; 1979 Jun; 63(6):1007-8. PubMed ID: 157222 [No Abstract] [Full Text] [Related]
25. Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors. Smith IE; Hedley DW; Powles TJ; McElwain TJ Cancer Treat Rep; 1978 Oct; 62(10):1427-33. PubMed ID: 709548 [No Abstract] [Full Text] [Related]
27. Chlorozotocin: phase II evaluation in patients with myeloma. Cornell CJ; Pajak TF; McIntyre OR Cancer Treat Rep; 1984 Apr; 68(4):685-6. PubMed ID: 6231990 [No Abstract] [Full Text] [Related]
28. Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. Von Hoff DD; Amato DA; Kaufman JH; Falkson G; Cunningham TJ Am J Clin Oncol; 1984 Apr; 7(2):135-9. PubMed ID: 6230929 [TBL] [Abstract][Full Text] [Related]
29. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group. Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924 [TBL] [Abstract][Full Text] [Related]
30. [Results of antineoplastic chemotherapy based on the oncobiogram]. Ebert A; Lenk H; Geyer J; Tanneberger S Arch Geschwulstforsch; 1989; 59(6):455-61. PubMed ID: 2596959 [TBL] [Abstract][Full Text] [Related]
31. Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer. Talley RW; Samson MK; Brownlee RW; Samhouri AM; Fraile RJ; Baker LH Eur J Cancer (1965); 1981 Mar; 17(3):337-43. PubMed ID: 6455296 [No Abstract] [Full Text] [Related]
32. [Curability of malignant neoplasms: value and limitations of chemotherapy]. Alberto P Schweiz Med Wochenschr; 1978 Dec; 108(49):1930-4. PubMed ID: 219468 [TBL] [Abstract][Full Text] [Related]
33. Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma. Berman E; Casper ES; Howard J; Wittes RE Cancer Treat Rep; 1984 Apr; 68(4):679-80. PubMed ID: 6585272 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Martín-Algarra S; Espinosa E; Rubió J; López López JJ; Manzano JL; Carrión LA; Plazaola A; Tanovic A; Paz-Ares L Eur J Cancer; 2009 Mar; 45(5):732-5. PubMed ID: 19186051 [TBL] [Abstract][Full Text] [Related]
35. Survey of human polyomavirus (JCV, BKV) infections in 139 patients with lung cancer, breast cancer, melanoma, or lymphoma. Hogan TF; Padgett BL; Walker DL; Borden EC; Frias Z Prog Clin Biol Res; 1983; 105():311-24. PubMed ID: 6304768 [TBL] [Abstract][Full Text] [Related]
36. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Schöffski P; Blay JY; De Greve J; Brain E; Machiels JP; Soria JC; Sleijfer S; Wolter P; Ray-Coquard I; Fontaine C; Munzert G; Fritsch H; Hanft G; Aerts C; Rapion J; Allgeier A; Bogaerts J; Lacombe D Eur J Cancer; 2010 Aug; 46(12):2206-15. PubMed ID: 20471824 [TBL] [Abstract][Full Text] [Related]
37. [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)]. Mathé G; Schein PS; De Vassal F; Serrou B; Imbach JL Sem Hop; 1982 Sep; 58(33):1867-71. PubMed ID: 6293062 [TBL] [Abstract][Full Text] [Related]
38. Phase II clinical evaluation of 4'-epi-doxorubicin. Hurteloup P; Cappelaere P; Armand JP; Mathé G Cancer Treat Rep; 1983 Apr; 67(4):337-41. PubMed ID: 6573956 [TBL] [Abstract][Full Text] [Related]
39. Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity. Macdonald JS; Hoth D; Schein PS Recent Results Cancer Res; 1980; 70():83-9. PubMed ID: 6444466 [TBL] [Abstract][Full Text] [Related]
40. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations. Ahmann FR; Meyskens FL; Moon TE; Durie BG; Salmon SE Cancer Res; 1982 Nov; 42(11):4495-8. PubMed ID: 6897012 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]